Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Abbott Japan Names Mr Sakamoto as President, Mr Honda as Vice President
April 3, 2013
- Janssen Poised to Keep Up Double-Digit Growth, Focus on 5 Therapeutic Areas: Japan Pres. Goodwin
April 3, 2013
- Kaketsuken also Files NDA for Cell Culture-Based New Influenza Vaccine
April 3, 2013
- Taiho Assigns 54 Oncology MRs according to Cancer Type
April 3, 2013
- AZ Takes Over Rights to Byetta and Bydureon; Bydureon Expected to Be Launched in May
April 2, 2013
- DSP Signs Agreement with Edison Pharmaceuticals of US for Mitochondrial Disease Treatments
April 2, 2013
- Gabriel Baertschi Takes Over as President of AZ K.K.
April 2, 2013
- MTPC Obtains Approval of SGLT-2 Inhibitor Canagliflozin in US
April 2, 2013
- 3 Companies’ Midterm Plans Foresee Poor Outlook for Domestic Market with “For-Reference-Only Figures,” “No Figures,” “Zero Growth”
April 2, 2013
- Mr Ninomiya Appointed as New President, Mr Mitani Exits to Become Advisor: Novartis Pharma
April 1, 2013
- Announcement: 6th annual Marketing Excellence Japan 2013 – Hilton Tokyo, May 14 – 15
April 1, 2013
- Dainippon Sumitomo Pharma Ties Up with Venture Company to Commercialize iPS Cell Therapy for Retinal Disease
April 1, 2013
- EMA Accepts Shionogi’s MAA for Ospemifene
April 1, 2013
- Asklep to Establish Joint Venture Company with US CRO ReSearch Pharmaceutical Services
April 1, 2013
- GSK's Operating Profit Down 22% in 2012 due to Cervarix Sales Drop
March 29, 2013
- Takeda Files NDA for Fixed-Dose Combination of Takepron, Low-Dose Aspirin in Japan
March 29, 2013
- Takeda Files NDAs for Cell Culture-Based New Flu Vaccines
March 29, 2013
- Shionogi Settles Crestor Lawsuit in US
March 28, 2013
- Equa Tops February Detailing Ranking in GP, HP Markets, Driven by Expanded Concurrent Use: Rep Track Survey
March 28, 2013
- First Time NDA Filed in Japan for Meningococcal Vaccine: Sanofi
March 28, 2013
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…